Erratum: Novel drugs and drug combinations for treating tuberculosis (BMJ (2014) 349 (g5948) DOI:10.1136/bmj.g5948));Novel drugs and drug combinations for treating tuberculosis

BMJ (Online)

Volumn 349, Issue , 2014, Pages

  Munang, Melinda L ^a,b   O'Shea, Matthew K ^a,c   Dedicoat, Martin ^a  

^a BIRMINGHAM HEARTLANDS HOSPITAL   (United Kingdom)

^b UNIVERSITY OF WARWICK   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BEDAQUILINE; DELAMANID; ETHAMBUTOL PLUS ISONIAZID PLUS PYRAZINAMIDE PLUS RIFAMPICIN; ISONIAZID PLUS RIFAMPICIN; MOXIFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAPENTINE; DRUG COMBINATION; TUBERCULOSTATIC AGENT;

ANXIETY DISORDER; ARTHRALGIA; ARTICLE; COMBINATION CHEMOTHERAPY; COST EFFECTIVENESS ANALYSIS; DIZZINESS; DRUG CHOICE; DRUG CONTRAINDICATION; DRUG COST; DRUG EFFICACY; DRUG MONITORING; DRUG RESPONSE; DRUG SAFETY; HEADACHE; HUMAN; HYPOTENSION; LATENT TUBERCULOSIS; LIVER TOXICITY; LUNG TUBERCULOSIS; MULTIDRUG RESISTANT TUBERCULOSIS; NAUSEA; NAUSEA AND VOMITING; PARESTHESIA; PATIENT INFORMATION; QT PROLONGATION; RISK ASSESSMENT; TENDINITIS; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREMOR; TUBERCULOSIS; VOMITING; CASE REPORT; DRUG COMBINATION; MALE; MIDDLE AGED;

ANTITUBERCULAR AGENTS; DRUG COMBINATIONS; HUMANS; MALE; MIDDLE AGED; TUBERCULOSIS;

EID: 84908147300     PISSN: 09598146     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.g6563     Document Type: Erratum

References (31)

1. World Health Organization. Global tuberculosis report 2013. WHO, 2013.
2. Espinal MA, Laszlo A, Simonsen L, Boulahbal F, Kim SJ, Reniero A, et al. Global trends in resistance to antituberculosis drugs. N Engl J Med 2001;344:1294-303.
3. Dye C, Glaziou P, Floyd K, Raviglione M. Prospects for TB elimination. Annu Rev Public Health 2013;34:271-86.
4. Hong Kong Chest Service/British Medical Research Council. Five-year follow-up of a controlled trial of five 6-month regimens of chemotherapy for pulmonary tuberculosis. Am Rev Respir Dis 1987;136:1339-42.
5. Hong Kong Chest Service/British Medical Research Council. Controlled trial of 2, 4, and 6 months of pyrazinamide in 6-month, three-times-weekly regimens for smear-positive pulmonary tuberculosis, including an assessment of a combined preparation of isoniazid, rifampin, and pyrazinamide: results at 30 months. Am Rev Respir Dis 1991;143:700-6.
6. Laserson KF, Kenyon AS, Kenyon TA, Layloff T, Binkin NJ. Substandard tuberculosis drugs on the global market and their simple detection. Int J Tuberc Lung Dis 2001;5:448-54.
7. Albanna AS, Smith BM, Cowan D, Menzies D. Fixed-dose combination antituberculosis therapy: a systematic review and meta-analysis. Eur Respir J 2013;42:721-32.
8. World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. WHO, 2011.
9. Burman WJ, Goldberg S, Johnson JL Muzanye G, Engle M, Mosher AW, et al. Moxifloxacin versus ethambutol in the first 2 months of treatment for pulmonary tuberculosis. Am J Respir Crit Care Med 2006;174:331-8.
10. Conde MB, Efron A, Loredo C, De Souza GR, Grac¸a NP, Cezar MC, et al. Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomized, controlled phase II trial. Lancet 2009;373:1183-9.
11. Dorman SE, Johnson JL, Goldberg S, Muzanye G, Padayatchi N, Bozeman L, et al. Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis. Am J Respir Crit Care Med 2009;180:273-80.
12. Jindani A, Hatherill M, Charalambous S, Mungofa S, Zizhou S, van Dijk J, et al. A multicentre randomized clinical trial to evaluate high dose rifapentine with a quinolone for treatment of pulmonary TB: the RIFAQUIN trial [abstract 147LB]. 20th Conference on Retroviruses and Opportunistic Infections, Atlanta, USA, 2013.
13. Gillespie SH, Crook AM, McHugh TD, Mendel CM, Meredith SK, Murray SR, et al. Four month moxifloxacin based regimens for drug sensitive tuberculosis. N Engl J Med 2014; published online 7 Sept.
14. Andries K, Verhasselt P, Guillemont J, Göhlmann HW, Neefs JM, Winkler H, et al. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science 2005;307:223-7.
15. Diacon AH, Pym A, Grobusch MP, de los Rios JM, Gotuzzo E, Vasilyeva I, et al. Multi drug resistant tuberculosis and culture conversion with bedaquiline. N Engl J Med 2014;371:723-32.
16. Matsumoto M, Hashizume H, Tomishige T, Kawasaki M, Tsubouchi H, Sasaki H, et al. OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice. PLoS Med 2006;3:e466.
17. Gler MT, Skripconoka V, Sanchez-Garavito E, Xiao H, Cabrera-Rivero JL, Dante E, et al. Delamanid for multidrug-resistant pulmonary tuberculosis. N Engl J Med 2012;366:2151-60.
18. Skripconoka V, Danilovits M, Pehme L, Tomson T, Skenders G, Kummik T, et al. Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis. Eur Respir J 2013;41:1393-400.
19. US National Institutes of Health. Safety and efficacy trial of delamanid for 6 months in patients with multidrug resistant tuberculosis. http://clinicaltrials.gov/ct2/show/NCT01424670.
20. Smieja MJ, Marchetti CA, Cook DJ, Smaill FM. Isoniazid for preventing tuberculosis in non-HIV infected persons. Cochrane Database Syst Rev 2000;2:CD001363.
21. Ena J, Valls V. Short-course therapy with rifampin plus isoniazid, compared with standard therapy with isoniazid, for latent tuberculosis infection: a meta-analysis. Clin Infect Dis 2005;40:670-6.
22. Gao X-F, Li J, Yang Z-W, Li Y-P. Rifapentine vs. rifampicin for the treatment of pulmonary tuberculosis: a systematic review. Int J Tuberc Lung Dis 2009;13:810-9.
23. Sterling TR, Villarino ME, Borisov AS, Shang N, Gordin F, Bliven-Sizemore E, et al. Three months of rifapentine and isoniazid for latent tuberculosis infection. N Engl J Med 2011;365:2155-66.
24. UK Clinical Research Network. The HALT-LTBI study: phase IV, multi-site, unblinded, randomised trial of prophylactic daily rifampicin/isoniazid vs. weekly rifapentine/isoniazid for latent tuberculosis infection (LTBI). http://public.ukcrn.org.uk/search/StudyDetail.aspx?StudyID=16214.
25. Wang PY, Xie SY, Hao Q, Zhang C, Jiang BF. NAT2 polymorphisms and susceptibility to anti-tuberculosis drug-induced liver injury: a meta-analysis. Int J Tuberc Lung Dis 2012;16:589-95.
26. Tulkens PM, Arvis P, Kruesmann F. Moxifloxacin safety: an analysis of 14 years of clinical data. Drugs R D 2012;12:71-100.
27. World Health Organization. Fixed-dose combinations for HIV/AIDS, tuberculosis, and malaria - report of a meeting held 16-18 December 2003 Geneva. http://apps.who.int/medicinedocs/en/d/Js6172e/.
28. Takiff H, Guerrero E. Current prospects for the fluoroquinolones as first-line tuberculosis therapy. Antimicrob Agents Chemother 2011;55:5421-9.
29. World Health Organization. The use of bedaquiline in the treatment of multidrug-resistant tuberculosis: interim policy guidance. WHO, 2013.
30. Shepardson D, MacKenzie WR. Update on cost-effectiveness of a 12-dose regimen for latent tuberculous infection at new rifapentine prices. Int J Tuberc Lung Dis 2014;18:751.
31. Shepardson D, Marks SM, Chesson H, Kerrigan A, Holland DP, Scott N, et al. Cost-effectiveness of a 12-dose regimen for treating latent tuberculous infection in the United States. Int J Tuberc Lung Dis 2013;17:1531-7.